Specifically, EGFR L718Q and L792X mutated residues have been detected by next-generation sequencing (NGS) in samples from 99 NSCLC patients experiencing clinical resistance to osimertinib [35]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.